Chimeric Therapeutics (ASX:CHM) Net Margin %: 0.00% (As of Dec. 2025)


What is Chimeric Therapeutics Net Margin %?

Chimeric Therapeutics ASX:CHM +1.47% Net Margin % is 0.00% as of Dec. 2025. The stock has 1 warning sign investors should review. Among 947 Biotechnology companies, Chimeric Therapeutics ranks worse than 63.25% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Chimeric Therapeutics's Net Income for the six months ended in Dec. 2025 was A$-11.22 Mil. Chimeric Therapeutics's Revenue for the six months ended in Dec. 2025 was A$0.00 Mil. Therefore, Chimeric Therapeutics's net margin for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for Chimeric Therapeutics's Net Margin % or its related term are showing as below:

ASX:CHM' s Net Margin % Range Over the Past 10 Years
Min: -262.79   Med: -262.79   Max: -262.79
Current: -262.79

ASX:CHM's Net Margin % is ranked worse than
63.25% of 947 companies
in the Biotechnology industry
Industry Median: -89.56 vs ASX:CHM: -262.79

Chimeric Therapeutics  (ASX:CHM) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Chimeric Therapeutics Net Margin % Related Terms

Chimeric Therapeutics Net Margin % Historical Data

* Premium members only.

The historical data trend for Chimeric Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chimeric Therapeutics Net Margin % Chart

Chimeric Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Net Margin %
0.00 0.00 0.00 0.00 -262.79

Chimeric Therapeutics Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ASX:CHM vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, Chimeric Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's Net Margin % falls into.


Chimeric Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Chimeric Therapeutics's Net Margin for the fiscal year that ended in Jun. 2025 is calculated as

Net Margin=Net Income (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=-10.43/3.969
=-262.79 %

Chimeric Therapeutics's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-11.216/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Chimeric Therapeutics (ASX:CHM) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Chimeric Therapeutics and its competitors. According to the industry distribution chart, Chimeric Therapeutics ranks #599 out of 947 companies in the Biotechnology industry, placing it in the top 63.3%.
Is Chimeric Therapeutics' Net Margin % too high?
Chimeric Therapeutics' current Net Margin % is 0.00%. Based on the distribution chart, Chimeric Therapeutics ranks #599 out of 947 companies in the Biotechnology industry, which is below the industry midpoint.
How does Chimeric Therapeutics' Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chimeric Therapeutics ranks #599 out of 947 companies for Net Margin %. This places Chimeric Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Chimeric Therapeutics and its competitors. Chimeric Therapeutics's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (ASX:CHM) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Chimeric Therapeutics (ASX:CHM), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chimeric Therapeutics Business Description

Address 62 Lygon Street, Level 3, Carlton, Melbourne, VIC, AUS, 3053
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.